Single-Stock ETFs Are Emerging Rapidly, but They Could Be Risky.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 10 2025
0mins
Should l Buy UNH?
Source: Barron's
Emergence of Leveraged Funds: The article highlights the rise of leveraged single-stock exchange-traded funds (ETFs) in the U.S. market this year, indicating a trend towards more speculative investment strategies.
Casino-like Environment: It suggests that the proliferation of these financial products reflects a broader shift in America’s investment landscape, likening it to a casino where high-risk gambling is becoming the norm.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy UNH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on UNH
Wall Street analysts forecast UNH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for UNH is 397.82 USD with a low forecast of 330.00 USD and a high forecast of 444.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 278.910
Low
330.00
Averages
397.82
High
444.00
Current: 278.910
Low
330.00
Averages
397.82
High
444.00
About UNH
UnitedHealth Group Incorporated is a healthcare and well-being company. Its segments include Optum Health, Optum Insight, Optum Rx, and UnitedHealthcare, which includes UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement and UnitedHealthcare Community & State. Optum Health offers comprehensive and patient-centered care, addressing the physical, mental, social, and financial well-being. Optum Health delivers primary, specialty and surgical care; helps patients and providers navigate and address complex, chronic and behavioral health needs. Optum Insight connects the healthcare system with services, analytics and platforms that make clinical, administrative and financial processes simpler and more efficient for all participants in the healthcare system. Optum Rx offers a range of pharmacy care services through retail pharmacies, through home delivery, specialty and community health pharmacies and the provision of in-home and community-based infusion services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of VONE Stock Performance
- Price Range Analysis: VONE's stock has a 52-week low of $218.75 and a high of $316.38, with the last trade at $314.58, indicating that the stock is nearing its high point, which may attract investor interest.
- Technical Analysis Tool: Comparing the current stock price to the 200-day moving average can provide valuable insights for investors, helping to assess market trends and optimal buying or selling opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade similarly to stocks, where investors buy and sell 'units' that can be created or destroyed based on investor demand, impacting the underlying holdings of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs helps identify significant inflows (new units created) or outflows (old units destroyed), which can affect the performance of individual stocks held within the ETFs.
See More
Income Investors Face Choices Amid Rising Treasury Yields
- UnitedHealth Membership Loss: The company anticipates losing up to 2.8 million members due to rising medical costs, resulting in a 20% drop in stock price following its Q4 earnings release, reflecting market concerns over profitability.
- Ryman's Performance Decline: Ryman Hospitality Properties reported a 15.5% drop in adjusted funds from operations (AFFO) per unit in Q3, primarily due to planned renovations and an increase in short-term cancellations, although bookings are up nearly 8% this year.
- ONEOK's Significant Earnings Growth: ONEOK's adjusted EBITDA surged 37% year-over-year to $2.1 billion in Q3, driven by contributions from EnLink and Medallion assets, showcasing its enhanced integration capabilities.
- Dividend Safety Analysis: Despite ongoing uncertainties, UnitedHealth's 3.2% dividend remains secure, with last year's free cash flow reaching $16 billion, nearly double the dividend payout, indicating strong financial health.
See More
Dividend Investing Strategies for All Ages
- Dividend Yield Basics: The dividend yield is calculated by dividing the annual dividend by the current stock price; for instance, Scruffy's Chicken Shack pays $1 quarterly, resulting in a 5% yield at an $80 share price, highlighting the need for caution when selecting high-yield stocks as falling prices can inflate yields.
- Attractiveness of Verizon: Verizon Communications boasts a recent dividend yield of 6.01%, and despite its slow growth, its $200 billion market cap and strong customer base make it a solid blue-chip investment, indicating stable cash flow and market position.
- Stability of Chevron: With a dividend yield of 3.97%, Chevron is a well-regarded energy company with nearly 40 years of annual dividend increases and a healthy balance sheet, making it a low-risk investment option with a market cap of $367 billion.
- Risks of UnitedHealth: UnitedHealth Group's dividend yield stands at 3.44%, but with nearly a 50% drop in stock price over the past year and regulatory challenges threatening profitability, investors should exercise caution despite its $247 billion market cap and potential for recovery.
See More
Mark Cuban Backs Bipartisan Healthcare Separation Bill
- Legislative Support: Billionaire entrepreneur Mark Cuban publicly endorses the 'Break Up Big Medicine Act,' introduced by Senators Hawley and Warren, which aims to force the separation of insurers, pharmacy benefit managers, and healthcare providers to lower healthcare costs in the U.S.
- Public Demand: Cuban describes the bill as a 'no brainer' on social media, urging President Trump to support the legislation, emphasizing that any Congress member opposing it does not want lower healthcare costs for Americans, reflecting strong public demand for healthcare reform.
- Antitrust Measures: Modeled after the 1933 Glass-Steagall Act, the bill seeks to prohibit common ownership among insurance companies, PBMs, and medical providers, aiming to combat monopolistic practices by 'Big Medicine' and protect the interests of working Americans.
- Enforcement and Impact: The bill empowers the FTC and DOJ to enforce these separations, with penalties including profit disgorgement for non-compliance, and proponents argue that it will eliminate self-dealing that currently inflates medical loss ratios and consumer premiums.
See More
Humana Earnings Outlook: Anticipating Updates on Medicare Advantage
- Earnings Report: Humana is set to report its fourth-quarter earnings on Wednesday.
- Industry Challenges: The insurer and its competitors are facing challenges due to proposed Medicare Advantage payment rates, which previously led to a market selloff.
See More
CVS Health Reports Strong Q4 Earnings, Reaffirms 2026 Guidance
- Earnings Beat: CVS Health reported adjusted earnings of $1.09 per share for Q4, surpassing analyst expectations of $0.99, indicating strong progress in its turnaround strategy under CEO David Joyner, which has bolstered investor confidence.
- Significant Revenue Growth: The company achieved $105.69 billion in revenue for the fourth quarter, an 8.2% increase year-over-year, with all business segments showing growth, particularly the insurance segment which saw over 10% revenue growth, signaling a recovery in market competitiveness.
- 2026 Profit Guidance Maintained: CVS expects full-year profit to range between $7 and $7.20 per share while maintaining its revenue guidance of at least $400 billion for 2026, despite facing $20 billion in market headwinds, reflecting the company's confidence in future growth.
- Strategic Adjustments Yield Results: Following the closure of 16 underperforming Oak Street Health locations, CVS's primary care provider is improving profitability, and combined with new technology investments and the acquisition of Rite Aid customers, is expected to further drive growth in its retail pharmacy business.
See More
Analysis of VONE Stock Performance
- Price Range Analysis: VONE's stock has a 52-week low of $218.75 and a high of $316.38, with the last trade at $314.58, indicating that the stock is nearing its high point, which may attract investor interest.
- Technical Analysis Tool: Comparing the current stock price to the 200-day moving average can provide valuable insights for investors, helping to assess market trends and optimal buying or selling opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade similarly to stocks, where investors buy and sell 'units' that can be created or destroyed based on investor demand, impacting the underlying holdings of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs helps identify significant inflows (new units created) or outflows (old units destroyed), which can affect the performance of individual stocks held within the ETFs.
See More
Income Investors Face Choices Amid Rising Treasury Yields
- UnitedHealth Membership Loss: The company anticipates losing up to 2.8 million members due to rising medical costs, resulting in a 20% drop in stock price following its Q4 earnings release, reflecting market concerns over profitability.
- Ryman's Performance Decline: Ryman Hospitality Properties reported a 15.5% drop in adjusted funds from operations (AFFO) per unit in Q3, primarily due to planned renovations and an increase in short-term cancellations, although bookings are up nearly 8% this year.
- ONEOK's Significant Earnings Growth: ONEOK's adjusted EBITDA surged 37% year-over-year to $2.1 billion in Q3, driven by contributions from EnLink and Medallion assets, showcasing its enhanced integration capabilities.
- Dividend Safety Analysis: Despite ongoing uncertainties, UnitedHealth's 3.2% dividend remains secure, with last year's free cash flow reaching $16 billion, nearly double the dividend payout, indicating strong financial health.
See More
Dividend Investing Strategies for All Ages
- Dividend Yield Basics: The dividend yield is calculated by dividing the annual dividend by the current stock price; for instance, Scruffy's Chicken Shack pays $1 quarterly, resulting in a 5% yield at an $80 share price, highlighting the need for caution when selecting high-yield stocks as falling prices can inflate yields.
- Attractiveness of Verizon: Verizon Communications boasts a recent dividend yield of 6.01%, and despite its slow growth, its $200 billion market cap and strong customer base make it a solid blue-chip investment, indicating stable cash flow and market position.
- Stability of Chevron: With a dividend yield of 3.97%, Chevron is a well-regarded energy company with nearly 40 years of annual dividend increases and a healthy balance sheet, making it a low-risk investment option with a market cap of $367 billion.
- Risks of UnitedHealth: UnitedHealth Group's dividend yield stands at 3.44%, but with nearly a 50% drop in stock price over the past year and regulatory challenges threatening profitability, investors should exercise caution despite its $247 billion market cap and potential for recovery.
See More
Mark Cuban Backs Bipartisan Healthcare Separation Bill
- Legislative Support: Billionaire entrepreneur Mark Cuban publicly endorses the 'Break Up Big Medicine Act,' introduced by Senators Hawley and Warren, which aims to force the separation of insurers, pharmacy benefit managers, and healthcare providers to lower healthcare costs in the U.S.
- Public Demand: Cuban describes the bill as a 'no brainer' on social media, urging President Trump to support the legislation, emphasizing that any Congress member opposing it does not want lower healthcare costs for Americans, reflecting strong public demand for healthcare reform.
- Antitrust Measures: Modeled after the 1933 Glass-Steagall Act, the bill seeks to prohibit common ownership among insurance companies, PBMs, and medical providers, aiming to combat monopolistic practices by 'Big Medicine' and protect the interests of working Americans.
- Enforcement and Impact: The bill empowers the FTC and DOJ to enforce these separations, with penalties including profit disgorgement for non-compliance, and proponents argue that it will eliminate self-dealing that currently inflates medical loss ratios and consumer premiums.
See More
Humana Earnings Outlook: Anticipating Updates on Medicare Advantage
- Earnings Report: Humana is set to report its fourth-quarter earnings on Wednesday.
- Industry Challenges: The insurer and its competitors are facing challenges due to proposed Medicare Advantage payment rates, which previously led to a market selloff.
See More
CVS Health Reports Strong Q4 Earnings, Reaffirms 2026 Guidance
- Earnings Beat: CVS Health reported adjusted earnings of $1.09 per share for Q4, surpassing analyst expectations of $0.99, indicating strong progress in its turnaround strategy under CEO David Joyner, which has bolstered investor confidence.
- Significant Revenue Growth: The company achieved $105.69 billion in revenue for the fourth quarter, an 8.2% increase year-over-year, with all business segments showing growth, particularly the insurance segment which saw over 10% revenue growth, signaling a recovery in market competitiveness.
- 2026 Profit Guidance Maintained: CVS expects full-year profit to range between $7 and $7.20 per share while maintaining its revenue guidance of at least $400 billion for 2026, despite facing $20 billion in market headwinds, reflecting the company's confidence in future growth.
- Strategic Adjustments Yield Results: Following the closure of 16 underperforming Oak Street Health locations, CVS's primary care provider is improving profitability, and combined with new technology investments and the acquisition of Rite Aid customers, is expected to further drive growth in its retail pharmacy business.
See More
